SUMMARY: This proposed rule is issued by the Deputy Administrator of the Drug Enforcement Administration (DEA) to modify the listing of the Marinol® formulation in schedule III so that certain generic drug products are also included in that listing. Several products are currently the subject of Abbreviated New Drug Applications (ANDAs) under review by the U.S. Food and Drug Administration (FDA). Each product is a generic formulation of Marinol® and contains dronabinol, the (-) isomer of delta-9- (trans)-tetrahydrocannabinol (THC), which is a schedule I controlled substance. Due to variations in formulation, these generic Marinol® products do not meet the specific conditions specified in the current schedule III listing. This proposed action expands the schedule III listing to include formulations having naturally-derived dronabinol and products encapsulated in hard gelatin capsules. This would have the effect of transferring the FDAapproved versions of such generic Marinol® products from schedule I to schedule III.
Pharmas asked the DEA to reschedule because de-novo synthesis of cannabinoids is much costlier than them growing it. Now plant extracted cannabinoid medicines are legal.
I work in the cancer industry as a researcher. It is all bullshit, all about expanding the scientific-medical-industrial complex and not about helping people.
What scares big pharma and the government the most?
Healthy, Educated, Wealthy people who can grow their own food and medicine and not be dependent on the corporate granny state.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.